So I'll address the first part (cos I didn't say the rest and anyway absolutely agree with you):
The model of paid trials is great, and I think removes a lot of risk from ADO. It also means that ADO is now stronger than before, being able to say "no" to freebie work.
For me those are all great signs on the path to success. ADO becomes a safer investment as each day passes.
But we're discussing SP events, and I don't think that will move the SP. Paid trials is linear revenue growth. On *best* estimations 1 scientist costs say $150k (with on costs), say they bill at $200k. at 10 working trials you get $500k revenue, which will burn up in expansion/hiring/new trials.
We're not investing in a law (or consulting) firm (that makes good money billing) that bills for time. This is about the IP and the royalties that come from licensing that IP. If we're just after incremental revenue, we can just all go home now.
But... all you point out is positive, I totally agree that it's looking rosy at the moment, but again, I was discussing share price sensitive events.
ADO Price at posting:
14.5¢ Sentiment: Buy Disclosure: Held
(20min delay)